Comparative Pharmacology
Head-to-head clinical analysis: PROMETHACON versus ZYRTEC D 12 HOUR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROMETHACON versus ZYRTEC D 12 HOUR.
PROMETHACON vs ZYRTEC-D 12 HOUR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Promethazine is a phenothiazine derivative with antihistaminic (H1 receptor antagonist), antiemetic, sedative, and anticholinergic properties. It inhibits central and peripheral H1 receptors, blocks dopamine D2 receptors in the chemoreceptor trigger zone, and has weak alpha-adrenergic blockade.
Cetirizine is a second-generation antihistamine that selectively inhibits peripheral H1 receptors, reducing histamine-mediated allergic responses. Pseudoephedrine is a sympathomimetic amine that acts as a decongestant via alpha-adrenergic receptor agonism in the respiratory tract mucosa, causing vasoconstriction and reduced edema.
25-50 mg intramuscularly or intravenously every 4-6 hours as needed. Maximum intravenous rate: 25 mg/minute. Maximum daily dose: 150 mg.
1 tablet (5 mg cetirizine / 120 mg pseudoephedrine) orally every 12 hours. Maximum 2 tablets per 24 hours.
None Documented
None Documented
Terminal elimination half-life: 4-6 hours in healthy adults; prolonged to 10-14 hours in hepatic impairment
Cetirizine: 8-10 hours in healthy adults; increased in renal impairment (e.g., up to 30 hours in severe impairment). Pseudoephedrine: 5-8 hours (pH-dependent; longer in alkaline urine).
Renal (80%) as inactive metabolites, 20% fecal via bile
Cetirizine: 70% renal (unchanged), 10% fecal. Pseudoephedrine: 90% renal (unchanged), remainder metabolized and excreted in urine.
Category C
Category C
Antihistamine
Antihistamine and Decongestant Combination